M&A Deals and Trends in Pharmaceuticals Progress by Application & Development 2016 Analysis
ReportsWeb.com published “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the
(EMAILWIRE.COM, March 22, 2017 ) Report Summary
Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs
For more information about this report: http://www.reportsweb.com/partnerships-licensing-investments-and-manda-deals-and-trends-in-pharmaceuticals-q3-2016
Reasons to buy
- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001506946/sample
Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2016 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2016 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2016 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2016 18
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2016 19
2.4.1 Teva Pharma Raises USD15 Billion in Public Offering of Notes 19
2.4.2 Pfizer Acquires Medivation in Tender Offer 20
2.4.3 Shire Raises USD12.1 Billion in Public Offering of Notes 21
2.4.4 Gilead Sciences Raises USD5 Billion in Public Offering of Notes 21
2.4.5 Johnson & Johnson to Acquire Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 22
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 23
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2016 23
3.1.1 Top M&A Deals in Q3 2016 24
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2015 - Q3 2016 25
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2016 26
3.2.1 Top Initial Public Offerings in Q3 2016 27
3.2.2 Top Secondary Offerings in Q3 2016 27
3.2.3 Top PIPE Deals in Q3 2016 28
3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2015 - Q3 2016 28
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2016 30
3.3.1 Top Venture Financing Deals in Q3 2016 31
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2016 32
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2016 32
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2015 - Q3 2016 33
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q3 2015 - Q3 2016 35
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2015 - Q3 2016 36
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2016 37
3.4.1 Top Private Equity Deals in Q3 2016 38
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2015 - Q3 2016 39
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2016 40
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2016 40
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2015 - Q3 2016 42
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 44
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2016 45
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2016 46
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2016 46
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 47
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2015 - Q3 2016 49
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2015 - Q3 2016 50
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 52
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2016 54
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2016 54
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 56
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2016 57
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2016 58
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2016 58
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2015 - Q3 2016 59
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2015 - Q3 2016 61
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2015 - Q3 2016 63
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2015 - Q3 2016 64
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2015
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001506946/buying
Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs
For more information about this report: http://www.reportsweb.com/partnerships-licensing-investments-and-manda-deals-and-trends-in-pharmaceuticals-q3-2016
Reasons to buy
- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001506946/sample
Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2016 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2016 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2016 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2016 18
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2016 19
2.4.1 Teva Pharma Raises USD15 Billion in Public Offering of Notes 19
2.4.2 Pfizer Acquires Medivation in Tender Offer 20
2.4.3 Shire Raises USD12.1 Billion in Public Offering of Notes 21
2.4.4 Gilead Sciences Raises USD5 Billion in Public Offering of Notes 21
2.4.5 Johnson & Johnson to Acquire Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 22
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 23
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2016 23
3.1.1 Top M&A Deals in Q3 2016 24
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2015 - Q3 2016 25
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2016 26
3.2.1 Top Initial Public Offerings in Q3 2016 27
3.2.2 Top Secondary Offerings in Q3 2016 27
3.2.3 Top PIPE Deals in Q3 2016 28
3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2015 - Q3 2016 28
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2016 30
3.3.1 Top Venture Financing Deals in Q3 2016 31
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2016 32
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2016 32
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2015 - Q3 2016 33
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q3 2015 - Q3 2016 35
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2015 - Q3 2016 36
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2016 37
3.4.1 Top Private Equity Deals in Q3 2016 38
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2015 - Q3 2016 39
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2016 40
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2016 40
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2015 - Q3 2016 42
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 44
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2016 45
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2016 46
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2016 46
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 47
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2015 - Q3 2016 49
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2015 - Q3 2016 50
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 52
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2016 54
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2016 54
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 56
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2016 57
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2016 58
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2016 58
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2015 - Q3 2016 59
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2015 - Q3 2016 61
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2015 - Q3 2016 63
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2015 - Q3 2016 64
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2015
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001506946/buying
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results